Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism

This is an open-label, multinational, multicenter, long-term safety and efficacy extension trial in patients with Congenital Hyperinsulinism (CHI) who completed either ZP4207-17103 (NCT04172441) or ZP4207-17109 (NCT03777176) (defined as lead-in trials). The primary objective is to evaluate the long-term safety of dasiglucagon administered as a subcutaneous (SC) infusion in children with CHI.

NCT Number	NCT03941236
Lead Sponsor	Zealand Pharma
Conditions	Congenital Hyperinsulinism
Enrollment	42 participants
Start Date	2019-05-02
Primary Completion	2025-01-28 (estimated)
Study Completion	2026-05-26 (estimated)
Updated on ClinicalTrials.gov	2026-08-03